| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| LB PHARMACEUTICALS INC | Chief Executive Officer, Director | Employee Stock Option (Right to Buy) | 971,828 | 10 Sep 2025 | Direct | ||
| Lyell Immunopharma, Inc. | Chief General Counsel | Option (right to buy) | 300,000 | 16 Mar 2022 | Direct | ||
| Terns Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 45,000 | 11 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | 10 Sep 2025 | 5 | $0 | 4 | Chief Executive Officer, Director | 12 Sep 2025, 18:25 |
| LBRX | LB PHARMACEUTICALS INC | 10 Sep 2025 | 0 | $0 | 3 | Chief Executive Officer, Director | 10 Sep 2025, 19:31 |
| TERN | Terns Pharmaceuticals, Inc. | 11 Jun 2025 | 1 | $0 | 4 | Director | 12 Jun 2025, 17:43 |
| TERN | Terns Pharmaceuticals, Inc. | 18 Nov 2024 | 1 | $0 | 4 | Director | 19 Nov 2024, 18:30 |
| TERN | Terns Pharmaceuticals, Inc. | 18 Nov 2024 | 0 | $0 | 3 | Director | 19 Nov 2024, 18:22 |
| LYEL | Lyell Immunopharma, Inc. | 16 Mar 2022 | 1 | $0 | 4 | Chief General Counsel | 18 Mar 2022, 16:11 |
| LYEL | Lyell Immunopharma, Inc. | 16 Jun 2021 | 0 | $0 | 3 | Chief General Counsel | 16 Jun 2021, 19:24 |